Sodium-glucose cotransporter 2 inhibitors and cardiovascular events among patients with type 2 diabetes and low-to-normal body mass index: a nationwide cohort study
The protective effect of SGLT2 inhibitors on cardiovascular events among patients with type 2 diabetes appeared to decrease with lower BMI and was not significant among patients with low-to-normal BMI (< 25.0 kg/m2). These findings suggest the importance of considering BMI when initiating SGLT2 inhibitors.
Authors
- O. Kenrik Duru (ORCID: https://orcid.org/0000-0001-8825-9460)
- Ryuichiro Yagi
- Toshiaki Komura (ORCID: https://orcid.org/0000-0002-7036-2467)
- Katherine R. Tuttle (ORCID: https://orcid.org/0000-0002-2235-0103)
- Motoko Yanagita (ORCID: https://orcid.org/0000-0002-0339-9008)
- Shingo Fukuma (ORCID: https://orcid.org/0000-0002-8379-8761)
- Naoki Kondo (ORCID: https://orcid.org/0000-0002-6425-6844)
- Motohiko Adomi (ORCID: https://orcid.org/0000-0003-4277-4509)
- Kosuke Inoue (ORCID: https://orcid.org/0000-0001-9614-8103)
- Yuichiro Mori (ORCID: https://orcid.org/0000-0001-7211-8970)
Institutions
- Boston University (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of California, Los Angeles (US)
- Providence College (US)
- University of Washington (US)
- Kyoto University (JP)
- Inland Northwest Health Services (US)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2024-10-22
- DOI
- https://doi.org/10.1186/s12933-024-02478-7
- Citations
- 7
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.50